The best indicator for ARK Genomic (ARKG)
We backtested 366 indicators across daily, weekly and hourly charts on real ARK Genomic (ARKG) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Stochastic
On the daily chart, this is the strongest risk-adjusted edge we found for ARK Genomic (ARKG) over ~11.6 years — beating buy-and-hold by 12.8% CAGR.
Best multi-indicator combo
Going long only when all 2 agree was the strongest confluence setup we found for ARK Genomic (ARKG) — beating buy-and-hold by 4.4% CAGR, out-of-sample. Fewer, higher-conviction trades than any single indicator.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Stochastic ✓ | Daily | 17.9% | 0.75 | -54.6% | 72.9% | 70 | 12.8% |
| 2 | CCI ✓ | Daily | 15.6% | 0.69 | -38.2% | 77.0% | 61 | 10.4% |
| 3 | Williams %R ✓ | Daily | 14.1% | 0.63 | -53.3% | 69.7% | 89 | 8.9% |
| 4 | Stochastic Momentum Index ✓ | Daily | 11.4% | 0.59 | -45.3% | 66.1% | 62 | 6.2% |
| 5 | Stochastic RSI ✓ | Daily | 10.0% | 0.53 | -35.8% | 64.4% | 90 | 4.8% |
| 6 | SSL Channel ✓ | Daily | 11.3% | 0.53 | -49.2% | 36.8% | 133 | 6.1% |
| 7 | Morning Star ✓ | Daily | 7.9% | 0.52 | -30.8% | 56.8% | 111 | 2.7% |
| 8 | Connors RSI-2 ✓ | Weekly | 8.6% | 0.5 | -45.8% | 67.9% | 28 | 3.4% |
| 9 | Predictive Ranges ✓ | Daily | 9.4% | 0.48 | -65.4% | 39.5% | 114 | 4.2% |
| 10 | Intraday Momentum Index ✓ | Daily | 10.4% | 0.47 | -70.4% | 63.9% | 36 | 5.2% |
| 11 | Momentum (50) ✓ | Weekly | 9.2% | 0.46 | -43.0% | 55.0% | 20 | 4.0% |
| 12 | Premier Stochastic ✓ | Weekly | 8.9% | 0.45 | -52.7% | 47.4% | 19 | 3.8% |
| 13 | Zero-Lag LSMA ✓ | Daily | 8.7% | 0.44 | -61.8% | 45.3% | 201 | 3.5% |
| 14 | Volume Flow Indicator | Daily | 8.5% | 0.44 | -54.4% | 33.3% | 18 | 3.3% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For ARK Genomic (ARKG), Stochastic on the daily timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More etf
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.